Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. ETF
  3. ALZN
ALZN logo

ALZN

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ALZN News

Alzamend Neuro Completes Clinical Phase of Phase II Trial for AL001 "Lithium in Brain" at Massachusetts General Hospital

Nov 19 2025Newsfilter

EXCLUSIVE: Alzamend Completes Clinical Phase of AL001 Study In Healthy Volunteers

Nov 19 2025Benzinga

Hewlett Packard Enterprise Set to Surge by 33%? Check Out 10 Leading Analyst Predictions for Thursday

Aug 21 2025Benzinga

Ascendiant Capital Reaffirms Buy Rating on Alzamend Neuro, Adjusts Price Target to $45

Aug 21 2025Benzinga

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Jul 28 2025Newsfilter

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

Jun 16 2025Newsfilter

Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone

May 29 2025Benzinga

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results

May 29 2025Benzinga

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories

May 29 2025TipRanks

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue

May 29 2025Benzinga

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

May 29 2025TipRanks

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 "Lithium in Brain" Study Taking Place at Massachusetts General Hospital

May 29 2025Newsfilter

EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants

May 13 2025Benzinga

Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested

May 11 2025TipRanks

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

May 07 2025Newsfilter

EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program

May 07 2025Benzinga